Twist Bioscience Corporation
NASDAQTwist Bioscience enters the week after earnings with a striking internal contradiction: executives are selling aggressively into a stock that has rallied more than 290% year-to-date, while short sellers are quietly rebuilding positions and options traders are turning more defensive. The insider selling is the standout angle here. CEO and founder Emily Leproust sold more than…
Snapshot as of 23 Sept 2026
Twist Bioscience enters the week after earnings with a striking internal contradiction: executives are selling aggressively into a stock that has rallied more than 290% year-to-date, while short sellers are quietly…
Twist Bioscience heads into the aftermath of its August 3 earnings print with a sharp post-results rally running headlong into one of the most stubborn short positions in biotech. The stock jumped 8.6% on the day of…
Twist Bioscience enters the week with the Street aggressively revising upward, even as a 40% one-month rally has already run well past most of those fresh targets. The analyst angle is the defining tension right now.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TWST — free to start on ORTEX.
Sign up for free →Open TWST on ORTEX